Symbols

SURF(Delisted)

Surface Oncology·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SURF

Surface Oncology, Inc.

A clinical-stage immuno-oncology company that developing immunotherapies for the tumor microenvironment

Industry

Established Date

Listing Date

04/19/2018

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.surfaceoncology.com

Security Type

Common stock

Office address

50 Hampshire Street, 8th Floor, Cambridge, MA 02139

Business

Introduction

Surface Oncology, Inc., incorporated under the laws of Delaware in April 2014, is a clinical-stage immuno-oncology company focused on leveraging its expertise in biological pathways, or TMEs, critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies.

Company Financials

EPS

SURF has released its 2023 Q2 earnings. EPS was reported at -0.46, versus the expected -0.34, missing expectations. The chart below visualizes how SURF has performed over recent quarters, highlighting trends in earnings surprises.